143 related articles for article (PubMed ID: 15816892)
21. Donor factors are associated with bronchiolitis obliterans syndrome after lung transplantation.
Hennessy SA; Hranjec T; Swenson BR; Kozower BD; Jones DR; Ailawadi G; Kron IL; Lau CL
Ann Thorac Surg; 2010 May; 89(5):1555-62. PubMed ID: 20417777
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation.
Glanville AR; Aboyoun CL; Morton JM; Plit M; Malouf MA
J Heart Lung Transplant; 2006 Aug; 25(8):928-34. PubMed ID: 16890113
[TBL] [Abstract][Full Text] [Related]
23. Early outcomes of lung transplantation for bronchiolitis obliterans syndrome after allogeneic haematopoietic stem cell transplantation: a single-centre experience.
Jung HS; Lee JG; Yu WS; Lee CY; Haam SJ; Paik HC
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):914-918. PubMed ID: 27481680
[TBL] [Abstract][Full Text] [Related]
24. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
Benden C; Haughton M; Leonard S; Huber LC
J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation.
Luckraz H; Sharples L; McNeil K; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2003 Mar; 22(3):287-91. PubMed ID: 12633696
[TBL] [Abstract][Full Text] [Related]
26. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
[TBL] [Abstract][Full Text] [Related]
27. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey.
Kapila A; Baz MA; Valentine VG; Bhorade SM;
J Heart Lung Transplant; 2015 Jan; 34(1):65-74. PubMed ID: 25447585
[TBL] [Abstract][Full Text] [Related]
28. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients.
Brugière O; Thabut G; Castier Y; Mal H; Dauriat G; Marceau A; Lesèche G
Chest; 2003 Jun; 123(6):1832-7. PubMed ID: 12796157
[TBL] [Abstract][Full Text] [Related]
29. Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients.
Mamessier E; Milhe F; Badier M; Thomas P; Magnan A; Reynaud-Gaubert M
J Heart Lung Transplant; 2006 May; 25(5):523-32. PubMed ID: 16678030
[TBL] [Abstract][Full Text] [Related]
30. Analysis of risk factors for the development of bronchiolitis obliterans syndrome.
Husain AN; Siddiqui MT; Holmes EW; Chandrasekhar AJ; McCabe M; Radvany R; Garrity ER
Am J Respir Crit Care Med; 1999 Mar; 159(3):829-33. PubMed ID: 10051258
[TBL] [Abstract][Full Text] [Related]
31. Primary graft dysfunction and long-term pulmonary function after lung transplantation.
Whitson BA; Prekker ME; Herrington CS; Whelan TP; Radosevich DM; Hertz MI; Dahlberg PS
J Heart Lung Transplant; 2007 Oct; 26(10):1004-11. PubMed ID: 17919620
[TBL] [Abstract][Full Text] [Related]
32. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
Groetzner J; Wittwer T; Kaczmarek I; Ueberfuhr P; Strauch J; Nagib R; Meiser B; Franke U; Reichart B; Wahlers T
Transplantation; 2006 Feb; 81(3):355-60. PubMed ID: 16477220
[TBL] [Abstract][Full Text] [Related]
33. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Lama VN; Murray S; Lonigro RJ; Toews GB; Chang A; Lau C; Flint A; Chan KM; Martinez FJ
Am J Respir Crit Care Med; 2007 Jun; 175(11):1192-8. PubMed ID: 17347496
[TBL] [Abstract][Full Text] [Related]
34. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction.
Girnita AL; Duquesnoy R; Yousem SA; Iacono AT; Corcoran TE; Buzoianu M; Johnson B; Spichty KJ; Dauber JH; Burckart G; Griffith BP; McCurry KR; Zeevi A
Am J Transplant; 2005 Jan; 5(1):131-8. PubMed ID: 15636621
[TBL] [Abstract][Full Text] [Related]
35. Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.
Verleden SE; Vos R; Vandermeulen E; Ruttens D; Bellon H; Heigl T; Van Raemdonck DE; Verleden GM; Lama V; Ross BD; Galbán CJ; Vanaudenaerde BM
Am J Transplant; 2016 Nov; 16(11):3262-3269. PubMed ID: 27367568
[TBL] [Abstract][Full Text] [Related]
36. The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation.
Krustrup D; Iversen M; Martinussen T; Schultz HH; Andersen CB
Clin Transplant; 2015 Mar; 29(3):179-84. PubMed ID: 25533723
[TBL] [Abstract][Full Text] [Related]
37. Early bronchiolitis obliterans syndrome shows an abnormality of perfusion not ventilation in lung transplant recipients.
Thompson BR; Ellis MJ; Stuart-Andrews C; Lopez M; Kedarisetty S; Snell GI; Prisk GK
Respir Physiol Neurobiol; 2015 Sep; 216():28-34. PubMed ID: 25981891
[TBL] [Abstract][Full Text] [Related]
38. Double lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome.
Fakhro M; Broberg E; Algotsson L; Hansson L; Koul B; Gustafsson R; Wierup P; Ingemansson R; Lindstedt S
J Cardiothorac Surg; 2017 Nov; 12(1):100. PubMed ID: 29178919
[TBL] [Abstract][Full Text] [Related]
39. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation.
Engelmann I; Welte T; Fühner T; Simon AR; Mattner F; Hoy L; Schulz TF; Gottlieb J
J Clin Virol; 2009 May; 45(1):47-53. PubMed ID: 19303808
[TBL] [Abstract][Full Text] [Related]
40. Are we near to an effective drug treatment for bronchiolitis obliterans?
Verleden GM; Vos R; Dupont L; Van Raemdonck DE; Vanaudenaerde BM; Verleden SE
Expert Opin Pharmacother; 2014 Oct; 15(15):2117-20. PubMed ID: 25154562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
